This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.
New brittle hip fractures;
New brittle vertebral fractures;
New other site fractures and/or total hip or neck of femur or L1-L4 T-value < -1.0;
Men or postmenopausal women;
bone metabolic diseases except for osteoporosis eg. a. (Osteogenesis Imperfecta, Paget's disease, Osteomalacia), b. Cushing's syndrome, c.hyperprolactinemia;
Having primary hyperparathyroidism or hypothyroidism;
Had or have osteomyelitis of the jaw or necrosis of the jaw;
GFR<30ml/min/1.73m2;
Parallel
Denosumab
DrugActive Comparator: 60mg of Denosumab treatment by subcutaneous injection
Teriparatide
DrugTeriparatide was sequentially treated with Denosumab
The main study：The incidence of new vertebral fractures
The main study：the incidence of new vertebral fractures (clinical and imaging) within 24 months of treatment
The sub study：The rate of change in BMD from baseline at lumbar spine in 24 months
The main study：New vertebral fractures in 12 months
The main study：New hip fractures, new fractures at other sites, and all new fractures at 12 and 24 months
The main study：The rate of BMD change from the baseline at the lumbar spine, total hip, and femoral neck in 12 and 24 months;
The main study：The rate of changes from baseline in serum type 1 collagen cross-linked C-terminal peptide (β-CTX) and type 1 procollagen N-terminal propeptide (P1NP) at 6, 12, and 24 months
Click on the lead sponsor to view all of their trials.
